Table 3 Comparison between group IIa and group IIb as regard age, sex, and drug history; SLEDAI; and MRI brain
From: Electroencephalography in systemic lupus erythematosus patients with neuropsychiatric manifestations
| Â | Group IIa | Group IIb | P value | Sig. | |
|---|---|---|---|---|---|
No. = 18 | No. = 12 | ||||
Age | Mean ± SD | 31.11 ± 11.36 | 30.50 ± 6.60 | 0.868 | NS |
Range | 15–55 | 20–42 | |||
Sex | Female | 16 (88.9% | 8 (66.7%) | 0.136 | NS |
Male | 2 (11.1%) | 4 (33.3%) | |||
Steroids | Positive | 13 (72.2%) | 8 (66.7%) | 0.745 | NS |
Steroid dose/day | Median (IQR) | 15 (10–30) | 17.5 (10–30) | 0.749 | NS |
Range | 5–30 | 5–30 | |||
Hydroxychloroquine | Positive | 9 (50.0%) | 7 (58.3%) | 0.654 | NS |
Azathioprine | Positive | 9 (50.0%) | 6 (50.0%) | 1.000 | NS |
Cyclophosphamide | Positive | 5 (27.8%) | 2 (16.7%) | 0.481 | NS |
MMF | Positive | 0 (0.0%) | 1 (8.3%) | 0.213 | NS |
SLEDAI | Median (IQR) | 15 (10–24) | 19 (12–25.5) | 0.396 | NS |
Range | 8–38 | 8–34 | |||
MRI brain | Positive | 10 (55.6%) | 6 (50.0%) | 0.765 | NS |